Q-omics provides the consensus-scored SLX1B profile across patient tissues and cancer cell-line models. SLX1B expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SLX1B is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, SLX1B RNA expression shows 6,959 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, LIHC, and UVM as cancer lineages where SLX1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLX1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLX1B survival associations across molecular data types. SLX1B RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLX1B RNA expression–survival associations across cancer types. High SLX1B expression shows unfavorable associations in KIRC, SARC, PRAD, KIRP and UVM, but favorable associations in CHOL. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SLX1B RNA expression.
This table summarizes SLX1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for SLX1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLX1B shows higher tumor expression in LIHC, KIRC, LUAD, LUSC, BLCA and COAD. The LIHC box plot shows higher SLX1B RNA expression in tumor versus normal tissue (log2 FC = +0.034, t-test p < 0.001).
This table shows molecular features associated with SLX1B in patient tissues and cancer cell lines. In patient samples, SLX1B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLX1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia.
